Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the safety, pharmacokinetics, and 4-week rapid
virologic response (RVR) of 3 different doses of ABT-267 (also known as ombitasvir) in
combination with pegylated interferon/ribavirin (pegIFN/RBV) compared with pegIFN/RBV alone
(ABT-267 placebo) in treatment naïve, hepatitis C virus (HCV), genotype 1-infected
participants.